HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance

Journal of Clinical Virology

Volumn 52, Issue 3, 2011, Pages 261-264

  Schirmer, P ^a   Winters, M ^b   Holodniy, M ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Emtricitabine; HBV; HIV; Tenofovir; Vaccine escape

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ASPARTATE AMINOTRANSFERASE; BICALUTAMIDE; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GOSERELIN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LOPINAVIR PLUS RITONAVIR; RALTEGRAVIR; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY TITER; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG BLOOD LEVEL; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN TISSUE; LIVER DISEASE; MALE; MIXED INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; THRUSH; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD; VIRUS MUTANT; VIRUS MUTATION; VIRUS STRAIN;

ADENINE; ANTIVIRAL AGENTS; COINFECTION; DEOXYCYTIDINE; DRUG RESISTANCE, VIRAL; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; PHOSPHONIC ACIDS; VIRAL LOAD; VIREMIA;

EID: 81155159721     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.07.014     Document Type: Article

References (14)

1. Martin-Carbonero L., Soriano V. New paradigms for treating hepatitis B in HIV/hepatitis B virus co-infected patients. Journal of Antimicrobial Chemotherapy 2010, 65:379-382.
2. Lacombe K., Bottero J., Lemoine M., Boyd A., Girard P.M. HIV/hepatitis B virus co-infection: current challenges and new strategies. Journal of Antimicrobial Chemotherapy 2010, 65:10-17.
3. Launay O., van der Vliet D., Rosenberg A.R., Michel M., Piroth L., Rey D., et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA 2011, 305:1432-1440.
4. Locarnini S.A. Hepatitis B virus surface antigen and polymerase gene variants: potential virological and clinical significance. Hepatology 1998, 27:294-297.
5. Teo C-G., Locarnini S. Potential threat of drug-resistant and vaccine-escape HBV mutants to public health. Antiviral Therapy 2010, 15:445-449.
6. McMahon B.J., Alward W.L., Hall D.B., Heyward W.L., Bender T.R., Francis D.P., et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. The Journal of Infectious Diseases 1985, 151:599-603.
7. Sulkowski M. Viral hepatitis and HIV coinfection. Journal of Hepatology 2008, 48:353-367.
8. Gunther S., Li B.C., Miska S., Kruger D.H., Meisel H., Will H. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. Journal of Virology 1995, 69:5437-5444.
9. Snow-Lampart A., Chappell B., Sorbel J., Borroto-Esoda K., Miller M. Evaluation of potential virologic resistance in HBV polymerase among subjects with persistent viremia following up to 144 weeks of therapy with Tenofovir DF. 45th Annual Meeting of the European Association for the Study of Liver (EASL) 2010, p. Abstract 1022.
10. Ohkawa K., Takehara T., Tatsumi T., Ishida H., Deguchi M., Kagita M., et al. Alterations in hepatitis B virus nucleotide sequences in a chronic virus carrier from immunotolerant to immunoactive phase. Biochemical and Biophysical Research Communications 2010, 394:574-580.
11. Kisker C.T., Mahoney E.M., Arkin S., Maeder M.A., Donfield S.M., Evatt B.L. Changes in hepatitis B serologic titers in HIV+ and HIV- children with haemophilia. Haemophilia 1999, 5:354-359.
12. Biggar R.J., Goedert J.J., Hoofnagle J. Accelerated loss of antibody to hepatitis B surface antigen among immunodeficient homosexual men infected with HIV. The New England Journal of Medicine 1987, 316:630-631.
13. Truvada Product Information V. 2. Gilead.
14. Ratcliffe Le, Beadsworth M.B.J., Pennell A., Phillips M., Vilar F. Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients. AIDS 2011, 25:1051-1056.